These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 25712812)

  • 1. Etanercept in refractory lupus arthritis: An observational study.
    Cortés-Hernández J; Egri N; Vilardell-Tarrés M; Ordi-Ros J
    Semin Arthritis Rheum; 2015 Jun; 44(6):672-9. PubMed ID: 25712812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
    Aringer M; Graninger WB; Steiner G; Smolen JS
    Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
    Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
    Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.
    Garcia-Carrasco M; Mendoza-Pinto C; Sandoval-Cruz M; Soto-Vega E; Beltran-Castillo A; Jimenez-Hernandez M; Graillet D; Gonzalez L; Rojas-Rodriguez J; Pineda-Almazana A; Zamudio-Huerta L; Lopez-Colombo A
    Lupus; 2010 Feb; 19(2):213-9. PubMed ID: 19965944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
    Fanouriakis A; Adamichou C; Koutsoviti S; Panopoulos S; Staveri C; Klagou A; Tsalapaki C; Pantazi L; Konsta S; Mavragani CP; Dimopoulou D; Ntali S; Katsikas G; Boki KA; Vassilopoulos D; Konstantopoulou P; Liossis SN; Elezoglou A; Tektonidou M; Sidiropoulos P; Erden A; Sfikakis PP; Bertsias G; Boumpas DT
    Semin Arthritis Rheum; 2018 Dec; 48(3):467-474. PubMed ID: 29555348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to treat refractory arthritis in lupus?
    Artifoni M; Puéchal X
    Joint Bone Spine; 2012 Jul; 79(4):347-50. PubMed ID: 22341583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis.
    Cheng LE; Amoura Z; Cheah B; Hiepe F; Sullivan BA; Zhou L; Arnold GE; Tsuji WH; Merrill JT; Chung JB
    Arthritis Rheumatol; 2018 Jul; 70(7):1071-1076. PubMed ID: 29513931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of etanercept-methotrexate combination therapy in patients with rhupus: an observational study of non-glucocorticoid treatment for rheumatic diseases.
    Yang BB; Xiao H; Li XJ; Zheng M
    Discov Med; 2018 Jan; 25(135):14-20. PubMed ID: 29466690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response.
    Jónsdóttir T; Gunnarsson I; Risselada A; Henriksson EW; Klareskog L; van Vollenhoven RF
    Ann Rheum Dis; 2008 Mar; 67(3):330-4. PubMed ID: 17827182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric systemic lupus erythematosus in Thammasat University Hospital.
    Pusongchai T; Jungthirapanich J; Khositseth S
    J Med Assoc Thai; 2010 Dec; 93 Suppl 7():S283-93. PubMed ID: 21294427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept.
    Verazza S; Davì S; Consolaro A; Bovis F; Insalaco A; Magni-Manzoni S; Nicolai R; Marafon DP; De Benedetti F; Gerloni V; Pontikaki I; Rovelli F; Cimaz R; Marino A; Zulian F; Martini G; Pastore S; Sandrin C; Corona F; Torcoletti M; Conti G; Fede C; Barone P; Cattalini M; Cortis E; Breda L; Olivieri AN; Civino A; Podda R; Rigante D; La Torre F; D'Angelo G; Jorini M; Gallizzi R; Maggio MC; Consolini R; De Fanti A; Muratore V; Alpigiani MG; Ruperto N; Martini A; Ravelli A;
    Pediatr Rheumatol Online J; 2016 Dec; 14(1):68. PubMed ID: 27993144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
    Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
    J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission.
    Zen M; Saccon F; Gatto M; Montesso G; Larosa M; Benvenuti F; Iaccarino L; Doria A
    Rheumatology (Oxford); 2020 Jul; 59(7):1591-1598. PubMed ID: 31642908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.
    Flouri I; Markatseli TE; Voulgari PV; Boki KA; Papadopoulos I; Settas L; Zisopoulos D; Skopouli FN; Iliopoulos A; Bertsias GK; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
    Semin Arthritis Rheum; 2014 Feb; 43(4):447-57. PubMed ID: 24012040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical inquiry. What treatments relieve arthritis and fatigue associated with systemic lupus erythematosus?
    Jones DW; Wright D; Jankowski TA
    J Fam Pract; 2014 Oct; 63(10):607-17. PubMed ID: 25343158
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.
    Petri M; Magder LS
    Arthritis Rheumatol; 2018 Nov; 70(11):1790-1795. PubMed ID: 29806142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis.
    Ostendorf B; Iking-Konert C; Kurz K; Jung G; Sander O; Schneider M
    Ann Rheum Dis; 2005 Apr; 64(4):630-3. PubMed ID: 15345502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus.
    Islam MN; Hossain M; Haq SA; Alam MN; Ten Klooster PM; Rasker JJ
    Int J Rheum Dis; 2012 Feb; 15(1):62-8. PubMed ID: 22324948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.